Compare VERA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | TWST |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2021 | 2018 |
| Metric | VERA | TWST |
|---|---|---|
| Price | $39.90 | $48.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $80.56 | $48.75 |
| AVG Volume (30 Days) | 835.9K | ★ 1.4M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.89 |
| Revenue Next Year | $445.28 | $15.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $18.53 | $23.30 |
| 52 Week High | $56.05 | $57.88 |
| Indicator | VERA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 53.08 |
| Support Level | $19.84 | $25.67 |
| Resistance Level | $56.05 | $57.88 |
| Average True Range (ATR) | 1.86 | 3.13 |
| MACD | -0.21 | -0.82 |
| Stochastic Oscillator | 16.45 | 32.56 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.